Senseonics Holdings, Inc. (SENS)
Senseonics Holdings, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Germantown, MD, US. The stock last traded at $8.02, down 9.94% on the session, giving a market capitalisation of $439.3M. On trailing twelve-month figures it carries a trailing P/E of -3.43, a net margin of -204.2%. Its beta of 1.03 implies it has historically moved more than the broad market.
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
Senseonics Holdings, Inc. is most often compared with the following Healthcare names: